Femasys Inc
FEMY0.813USD
-0.007-0.82%
Market hours （ET）Quotes delayed by 15 min
22.02MMarket Cap
LossP/E TTM
More Details of Femasys Inc Company
Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
Company Info
Ticker SymbolFEMY
Company nameFemasys Inc
IPO dateJun 18, 2021
CEOMs. Kathy Lee-Sepsick
Number of employees69
Security typeOrdinary Share
Fiscal year-endJun 18
Address3950 Johns Creek Court
CitySUWANEE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code30024
Phone17705003910
Websitehttps://www.femasys.com/
Ticker SymbolFEMY
IPO dateJun 18, 2021
CEOMs. Kathy Lee-Sepsick
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
384.31K
+9.80%
Mr. Alistair Milnes
Mr. Alistair Milnes
Independent Director
Independent Director
5.67K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
80.00
--
Mr. Dov Elefant
Mr. Dov Elefant
Chief Financial Officer
Chief Financial Officer
--
--
Dr. James Liu, M.D.
Dr. James Liu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Independent Director
Independent Director
--
--
Mr. Daniel Currie
Mr. Daniel Currie
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Edward Uzialko, Jr.
Mr. Edward Uzialko, Jr.
Independent Director
Independent Director
--
--
Ms. Christine Thomas
Ms. Christine Thomas
Chief Regulatory and Clinical Officer
Chief Regulatory and Clinical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
384.31K
+9.80%
Mr. Alistair Milnes
Mr. Alistair Milnes
Independent Director
Independent Director
5.67K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
80.00
--
Mr. Dov Elefant
Mr. Dov Elefant
Chief Financial Officer
Chief Financial Officer
--
--
Dr. James Liu, M.D.
Dr. James Liu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
341.26K
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 18
Updated: Fri, Jul 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Chernett (Jorey)
4.99%
Dauntless Investment Group, LLC
4.84%
Uzialko (Edward R Jr.)
3.74%
The Vanguard Group, Inc.
2.54%
CM Management, LLC
1.31%
Other
82.58%
Shareholders
Shareholders
Proportion
Chernett (Jorey)
4.99%
Dauntless Investment Group, LLC
4.84%
Uzialko (Edward R Jr.)
3.74%
The Vanguard Group, Inc.
2.54%
CM Management, LLC
1.31%
Other
82.58%
Shareholder Types
Shareholders
Proportion
Individual Investor
10.52%
Investment Advisor
10.24%
Investment Advisor/Hedge Fund
1.26%
Hedge Fund
0.23%
Venture Capital
0.10%
Research Firm
0.09%
Bank and Trust
0.05%
Other
77.52%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
70
7.31M
22.48%
+821.23K
2025Q1
67
7.22M
24.70%
+706.34K
2024Q4
60
4.03M
17.61%
-312.38K
2024Q3
58
3.32M
14.71%
-994.98K
2024Q2
60
3.27M
14.50%
-951.60K
2024Q1
59
3.16M
17.88%
-1.13M
2023Q4
59
3.12M
17.80%
-765.84K
2023Q3
57
3.89M
25.74%
+6.18K
2023Q2
54
3.49M
25.26%
-520.59K
2023Q1
51
3.40M
28.73%
-4.68M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Chernett (Jorey)
1.62M
4.99%
+1.62M
--
Feb 19, 2025
Dauntless Investment Group, LLC
1.58M
4.84%
+145.30K
+10.16%
Mar 31, 2025
Uzialko (Edward R Jr.)
1.22M
3.74%
--
--
Apr 08, 2025
The Vanguard Group, Inc.
825.67K
2.54%
--
--
Mar 31, 2025
CM Management, LLC
425.00K
1.31%
--
--
Mar 31, 2025
Lee-Sepsick (Kathy)
384.31K
1.18%
+34.31K
+9.80%
Jun 02, 2025
Clear Creek Financial Management, LLC
270.37K
0.83%
+14.00K
+5.46%
Mar 31, 2025
Geode Capital Management, L.L.C.
245.51K
0.75%
+29.34K
+13.57%
Mar 31, 2025
Currie (Daniel Scott)
109.24K
0.34%
+19.61K
+21.88%
Jun 02, 2025
State Street Global Advisors (US)
56.37K
0.17%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
